BAY 1892005|CAS 2036352-13-1|DC Chemicals

Cas No.:	2036352-13-1
Chemical Name:	2-chloro-N-[4-(2-fluorophenyl)-1,3-thiazol-2-yl]acetamide
Synonyms:	BAY 1892005;2036352-13-1;HY-156967;EX-A8236;CS-0905202
SMILES:	ClCC(NC1=NC(=CS1)C1C=CC=CC=1F)=O
Formula:	C₁₁H₈ClFN₂Os
M.Wt:	270.710423469543
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

MSDS

Cat. No.	Product name	Field of application
DC73117	BAY 1892005	BAY 1892005 is a small molecule that modulate mutant p53 condensation and nuclear accumulation, binds covalently to mutant p53R175H and p53Y220C and shows stabilization of p53WT and p53Y220C, exhibits anti-proliferative activity in a set of cell lines wit
DC8599	SP 141	SP 141 is a cell-permeable inhibitor of Mdm2 (Ki = 28 nM).
DC9506	SJ-172550	SJ-172550 is the first MDMX inhibitor with EC50 of 0.84 uM; binds reversibly to MDMX and effectively kills retinoblastoma cells in which the expression of MDMX is amplified.
DC8144	Pifithrin-β (hydrobromide)	Pifithrin-β HBr (Cyclic Pifithrin-α HBr) is a potent p53 inhibitor with IC50 of 23 uM in an antiproliferative assay in the human ovarian carcinoma cell line, IGROV-1.
DC8454	Nutlin-3a	Nutlin-3a is arbitrarily referred to as enantiomer a because it appears as the first peak from chiral purification of racemic nutlin-3 and its absolute stereocenter assignment is not known.
DC3125	Nutlin-3	Nutlin 3 is a commercial available p53-MDM2 inhibitor, with Ki of 90 nM.
DC10957	MB725	MB725 is a small-molecule p53 mutant Y220C stabilizer, induces selective viability reduction in several p53-Y220C cancer cell lines (Huh7 cell IC50=10 uM).
DC11726	Milademetan	Milademetan (DS-3032) is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) induces G1 cell cycle arrest, senescence and apoptosis.
DC11837	RO-5963	RO-5963 is an inhibitor of the interaction of both MDM2 and MDMX with p53.
DC11669	CB-002	CB-002 is a novel small molecule that restores p53 function in mutant p53-expressing colorectal cancer cells without toxicity to normal human fibroblasts; increases expression of endogenous p53 target genes NOXA, DR5, and p21 and cell death; decreases the stability of mutant p53 in RXF393 cancer cells and an exogenously expressed R175H p53 mutant in HCT116 p53-null cells.